Quick Answer
iBio, Inc. reported Net Income Loss of -$18.38 million for the year ending 2025.
- iBio, Inc. showed an increase of +26.2% in Net Income Loss from 2024 to 2025.
- This data is from iBio, Inc.'s annual report (Form 10-K), filed with the SEC on September 5, 2025.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2012 to 2025), iBio, Inc.'s Net Income Loss has declined by 223.8%.
- Historical annual values: Fiscal year 2025: -$18.38 million | Fiscal year 2024: -$24.91 million | Fiscal year 2023: -$65.01 million | Fiscal year 2022: -$50.30 million | Fiscal year 2021: -$23.21 million | Fiscal year 2020: -$16.44 million | Fiscal year 2019: -$17.59 million | Fiscal year 2018: -$16.11 million | Fiscal year 2017: -$14.53 million | Fiscal year 2016: -$9.76 million | Fiscal year 2015: -$6.63 million | Fiscal year 2014: -$3.67 million | Fiscal year 2013: -$6.20 million | Fiscal year 2012: -$5.68 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: